Viking Therapeutics (VKTX) said Tuesday it has signed a deal with CordenPharma to manufacture and supply both the active pharmaceutical ingredient and finished product for Viking's VK2735 program for obesity.
Under the terms of the deal, Viking said it will pay $150 million between 2025 and 2028 to CordenPharma, which has committed to provide an annual supply of over 1 billion oral tablets of VK2735 as well as 100 million autoinjectors and 100 million vial and syringe products for the subcutaneous formulation of VK2735.
Viking said it retains ownership of all global rights to VK2735, its investigational dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for metabolic disorders like obesity.
The company said it is conducting a phase 2 oral dosing trial of VK2735 and expects to begin a phase 3 study for the subcutaneous formulation in Q2.
Viking's stock was down 2% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。